Further information:

Company Announcement no 14 / 2010

]]>

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Company Announcement no 13 /2010

]]>On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 12 / 2010
]]>The ordinary Annual General Meeting will be held on

Wednesday 24 March 2010 at 2.00 pm (CET)

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical pr (...)

Further information:

Company Announcement no 10 / 2010
]]>On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 9 / 2010

]]>In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

For further information please contact:

Company Announcement no 8 / 2010

]]>Further information:

Company Announcement no 7 / 2010

]]>In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

For further information please contact:

Company Announcement no 6 /2010
]]>In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

For further information please contact:

Company Announcement (...)]]>Company Announcement

Financial statement for 2009

In 2010, operating profit is expected to increase by around 10%

• Sales increased by 12% in Danish kroner and by 11% in local currencies.  

Sales of modern insulins increased by 24% (23% in local currencies).

Sales of NovoSeven® increased by 11% (10% in local currencies).

Sales of Norditropin® increased by 14% (10% in local currencies).

Sales in North America increased by 21% (15% in local currencies).

Sales in International Operations increased by 17% (19 (...)

Novo Nordisk announced today that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza® for the treatment of type 2 diabetes in adults.

Victoza® is the brand name approved in the US and Europe for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. In the US, Victoza® is indicated as an a (...)

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes.

Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes.

"The Japanese approval of Victoza® (...)

Novo Nordisk expects to provide an update on the regulatory process for liraglutide in connection with the announcement of the fina (...)